the cytoxic action of certain chemotherapeutic drugs may be enhanced more in tumours than in normal tissues by combining them with misonidazole (MISO) (see reviews by Brown, 1982; . This is particularly true of the alkylating agents and certain nitrosoureas. For instance, Martin et al., (1 981) reported a dose-modifying factor (DMF) of 2 when 1 mg/g MISO was combined with cyclophosphamide (Cy) against the WHFIB tumour, with no effect of MISO on the leucopenia induced by Cy. A similar result was obtained with melphalan.
In contrast, the radioprotective drug WR2721 has been reported to protect certain normal tissues to a greater extent than tumours from the cytotoxic action of Cy (Yuhas etal., 1980; Twentyman, 1981) , nitrogen mustard (Yuhas, 1979) , cisplatinum , and a range of cytoxic drugs including Cy, nitrogen mustard and cis-platinum (Wasserman et al., 1981) .
I have therefore combined MISO and WR2721 with either Cy or melphalan in an attempt to increase the effectiveness of the chemotherapeutic drugs in tumours due to MISO potentiation, while reducing their effects in normal tissues due to WR2721 protection, thus increasing the therapeutic ratio. The normal tissue endpoint was white cell depression.
The tumour used was the WHFIB tumour growing in inbred WHT/GyfBSVS mice. This is a poorly differentiated sarcoma derived from a fibrosarcoma which arose spontaneously in a WVHT mouse. It has been adapted for growth in vitro so that after treatment in vivo the response can be assessed in terms of tumour cell survival in vitro (George et al., 1977) . The methods used to obtain tumours and to assay cell survival after treatment have been described before (Martin et al., 1981) . Tumours were treated when they had reached a mean diameter of 6-8 mm, when the volume doubling time was about 3-5 days. The drugs were administered i.p. as a solution in normal saline, except for WR2721 which was dissolved in distilled water. They were dissolved immediately before use at a concentration such that the volume injected would be either 0-01 or 0-02 ml/g body wt.
Leucopenia induced by Cy or melphalan was assessed by drawing up a small volume of blood from the cut tip of the tail of a mouse lightly anaesthetized with penthrane into a heparinized capillary tube. The blood was then diluted in 0.2% acetic acid to lyse the red cells and the white cells were counted using a haemocytometer and phase contrast microscopy. At least 5 mice were used for each dose point.
It was shown previously that the cells of the WHFIB tumour are capable of recovering from the potentially lethal damage induced by Cy or melphalan (Martin et al., 1981 tumours were not excised until 24 h after the drug was given in order to assess its effect on cell survival. MISO has its greatest effect on Cy or melphalan toxicity when given 1 h before the drug (Martin et al., 1981) . WR2721 has its greatest radioprotective effect when given about 40 min before radiation Travis et al., 1982) . The injection schedule was therefore: MISO-20 min-WR2721-40 min-Cy or melphalan Fig. 1 shows the effect of Cy or melphalan on survival of the cells of the WHFIB tumour treated in vivo and assayed in vitro. The drugs were given either alone or in combination with MISO or WR2721, or MISO plus WR2721. The additive toxicities of MISO and WR2721 limits the amount of the 2 drugs that can be used together . Consequently the doses of the 2 were adjusted to ensure that there should be adequate potentiation of drug action by MISO and yet enough WR2721, on the basis of published results, to give chemoprotection if there is any. The doses of MISO and WR2721 were 500 and 400 mg/kg respectively with Cy and 800 and 300 mg/kg respectively with melphalan. The doses differed because whereas 500 mg/kg MISO potentiates the action of Cy upon the WHFIB tumour, a larger dose is needed with melphalan (McNally, unpublished data). MISO enhanced the action of Cy against the WHFIB tumour, giving a DMF of about 2 ( Fig. 1 (A) ). WR2721 had no effect on Cytoxicity or its potentiation by MISO. With melphalan, MISO gave a DMF of about 2-4. Again there was no effect of WR2721 either with or without MISO.
The data points in Fig. 1 or in combination, at the doses used, had no effect on tumour cell survival. The effect of Cy on the total white cell count in mice without tumours is shown in Fig. 2. Fig. 2(A) shows that the nadir in the white cell count was reached 3 days after injection of the Cy, with full recovery following a dose of 100 mg/kg by Day 7. Each data point in Fig. 2(A) represents the average white cell count for 5 mice. Previous studies have shown no effect of MISO on the extent of or the time course of the fall and subsequent recovery of the white cell count due to Cy (McNally et al., 1982) . Neither MISO or WR2721 alone, nor the two together, had any effect on the nadir following 100 mg/kg Cy or on the subsequent recovery in the white cell count (Fig 2(A) ). MISO and WR2721, either alone or in combination, also had no effect on control mice or the dose-effect curve for depression in white cell count at 3 days induced by Cy (Fig. 2(B) ). The points in Fig. 2(B Fig. 3 shows the effect of melphalan, either alone or with MISO or WR2721, or with both, on white cell depression assayed 5 days after injection. This had previously been found to be the time of the nadir in white cell count due to melphalan in this strain of mice . The points and error bars were obtained as described for Fig. 2(B) . As with Cy, MISO or WR2721 separately had no effect on the white cell depression due to melphalan. (Twentyman, 1981 1ISO 800 mg/kg; 2721 300 mg/kg).
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